Multiple Sclerosis Disease-Modifying Drugs in Children and Adolescents
| Autor: | Batysheva Tt, I. M. Drozdova, Bykova Ov, O. V. Kvasova, A. N. Boiko, Nankina Ia |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
education.field_of_study business.industry General Neuroscience Multiple sclerosis Population Legislation Pediatric age Disease Routine practice medicine.disease Clinical trial 03 medical and health sciences Pediatric patient 0302 clinical medicine Family medicine medicine 030212 general & internal medicine education business 030217 neurology & neurosurgery |
| Zdroj: | Neuroscience and Behavioral Physiology. 47:544-552 |
| ISSN: | 1573-899X 0097-0549 |
| DOI: | 10.1007/s11055-017-0433-z |
| Popis: | The vast majority of drugs for the treatment of multiple sclerosis (MS) have been developed and approved for the adult patient population. The place of these drugs in the treatment of children remains undefined not only in Russia, but also throughout the world. Despite the fact that studies of new drugs in the pediatric patient population is part of the routine practice of large pharmaceutical agencies such as the FDA and the EMA, treatment recommendations FOR pediatric MS patients are based less on long-term systematized experience of clinical studies as on a professional consensus of international expert associations, particularly the International Pediatric Multiple Sclerosis Study Group (IPMSSG). Clinical trials include small numbers of patients of pediatric age, minor compared with the number of participants in adult studies. There is therefore a need to develop new assessments evidencing the efficacy and safety of drugs for the treatment of MS in children and adolescents. This article presents the views of the IPMSSG on the treatment of pediatric MS, taking account of the characteristics of the Russian legislation and experience of Russian specialists. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink